DZ

EQS-News: CLAAS successfully closes €850 million credit line

Retrieved on: 
Tuesday, October 17, 2023

CLAAS has signed a €850 million revolving credit facility.

Key Points: 
  • CLAAS has signed a €850 million revolving credit facility.
  • This strengthens CLAAS in the long term," says Henner Böttcher, Chief Financial Officer of CLAAS.
  • The new transaction replaces the existing syndicated credit line of € 500 million from 2022.
  • The revolving credit facility is one of the standard financing instruments of the CLAAS Group and serves to secure short-term liquidity.

EQS-News: Amprion GmbH: Amprion again successful with green bond in volume of €1.2 billion

Retrieved on: 
Wednesday, August 30, 2023

The transmission system operator Amprion has once again successfully placed a green bond with a total nominal volume of €1.2 billion on the international capital market.

Key Points: 
  • The transmission system operator Amprion has once again successfully placed a green bond with a total nominal volume of €1.2 billion on the international capital market.
  • The green dual-tranche bond was issued within Amprion's €9 billion debt issuance programme.
  • The second tranche with a volume of €700 million has a maturity of 11 years and an interest coupon of 4.125% p. a.
    Peter Rüth, CFO of Amprion: “We have once again successfully placed a dual-tranche green bond.
  • Moody's has assigned a Baa1 rating to the newly issued dual-tranche green bond.

EQS-News: Allgeier SE: SDX, a Microsoft specialist in cloud software development and data analytics, joins the Allgeier Group

Retrieved on: 
Wednesday, August 23, 2023

Allgeier SE: SDX, a Microsoft specialist in cloud software development and data analytics, joins the Allgeier Group

Key Points: 
  • Allgeier SE: SDX, a Microsoft specialist in cloud software development and data analytics, joins the Allgeier Group
    The issuer is solely responsible for the content of this announcement.
  • Munich, August 23, 2023 – Microsoft partner SDX AG, which specializes in cloud software development and data analytics, joins the Allgeier Group.
  • Allgeier is one of Germany’s leading technology companies for digital transformation and offers customers a fully comprehensive software and IT services portfolio ranging from high-end software development to business efficiency solutions to support the digitization and transformation of business-critical processes.
  • Together, SDX and Allgeier are targeting strong growth for the Microsoft business unit - driven by high market demand.

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Retrieved on: 
Saturday, June 3, 2023

++Across all arms, one participant in the DZ arm had a response pending confirmation, which was confirmed after DCO date.

Key Points: 
  • ++Across all arms, one participant in the DZ arm had a response pending confirmation, which was confirmed after DCO date.
  • - Consistent ORR and PFS improvements were shown for the domvanalimab-containing arms in a post-hoc analysis of centrally confirmed PD-L1-high patients.
  • The addition of domvanalimab to zimberelimab did not increase the incidence of infusion-related reactions, consistent with the Fc-silent design of domvanalimab.
  • Neither Gilead nor Arcus has received approval from any regulatory authority for any use globally, and their safety and efficacy for the treatment of lung cancer have not been established.

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Retrieved on: 
Saturday, June 3, 2023

Across all arms, one participant in the DZ arm had a response pending confirmation, which was confirmed after DCO date.

Key Points: 
  • Across all arms, one participant in the DZ arm had a response pending confirmation, which was confirmed after DCO date.
  • Consistent ORR and PFS improvements were shown for the domvanalimab-containing arms in a post-hoc analysis of centrally confirmed PD-L1-high patients.
  • The addition of domvanalimab to zimberelimab did not increase the incidence of infusion-related reactions, consistent with the Fc-silent design of domvanalimab.
  • Neither Gilead nor Arcus has received approval from any regulatory authority for any use globally, and their safety and efficacy for the treatment of lung cancer have not been established.

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Retrieved on: 
Tuesday, May 9, 2023

ProQR Therapeutics NV.

Key Points: 
  • ProQR Therapeutics NV.
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference (TIDES USA), May 7-10, 2023 in San Diego, CA, USA.
  • 50% editing in liver of mice.
  • New optimizations are being evaluated (not disclosed in the presentation).

Djazagro, the Tradeshow for Agro-food Production, 5-8 June 2023, Palais Des Expositions Safex - Algiers

Retrieved on: 
Wednesday, March 29, 2023

It offers ideal and strategic opportunities through four days of discussions, meetings, talks and education.

Key Points: 
  • It offers ideal and strategic opportunities through four days of discussions, meetings, talks and education.
  • All the fields in the agri-food industry are represented, from processing to filling and from hygiene to food products.
  • Djaz’Innov : the innovation contest rewarding the best new products or processes presented by exhibitors: equipment, products, services or processes.
  • Agora des Experts: a chance to look into the future of the food industry.

EQS-News: VR Equitypartner GmbH: VR Equitypartner supports Cygna Labs in the acquisition of Nokia’s DDI business unit

Retrieved on: 
Thursday, March 16, 2023

Cygna Labs will be supported by Frankfurt-based private equity company VR Equitypartner (VREP), which holds a minority stake in the company.

Key Points: 
  • Cygna Labs will be supported by Frankfurt-based private equity company VR Equitypartner (VREP), which holds a minority stake in the company.
  • Cygna Labs is a leading software developer in the fields of network, cloud and security and one of the top three global DDI vendors.
  • The product will remain a standalone product line and has already been incorporated into Cygna Labs’ portfolio of managed service offerings.
  • Alexander Häcker, CEO of Cygna Labs Group, notes: “Cygna Labs continues to support large-scale enterprise customers that rely on our DDI products and services.

SIXT Stronger Than Ever Before in 2022: Record Revenue of More Than EUR 3 Billion, EBT Reaches Record High of EUR 550 million

Retrieved on: 
Tuesday, February 28, 2023

Alexander Sixt, Co-CEO of Sixt SE: “2022 was the second record year in a row for SIXT.

Key Points: 
  • Alexander Sixt, Co-CEO of Sixt SE: “2022 was the second record year in a row for SIXT.
  • Consolidated earnings before taxes (EBT) reached a record level of EUR 550.2 million, an increase of 24.4% over the previous year (EUR 442.2 million).
  • EBT was thus at the upper end of the range of EUR 500 million to EUR 550 million.
  • Group EBT in 2023 is projected to be in the range of EUR 430 million to EUR 550 million.

EQS-News: SIXT stronger than ever before in 2022: record revenue of more than EUR 3 billion, EBT reaches record high of EUR 550 million

Retrieved on: 
Tuesday, February 28, 2023

SIXT stronger than ever before in 2022: record revenue of more than EUR 3 billion, EBT reaches record high of EUR 550 million

Key Points: 
  • SIXT stronger than ever before in 2022: record revenue of more than EUR 3 billion, EBT reaches record high of EUR 550 million
    The issuer is solely responsible for the content of this announcement.
  • Alexander Sixt, Co-CEO of Sixt SE: “2022 was the second record year in a row for SIXT.
  • EBT was thus at the upper end of the range of EUR 500 million to EUR 550 million.
  • Group EBT in 2023 is projected to be in the range of EUR 430 million to EUR 550 million.